213 related articles for article (PubMed ID: 18495964)
1. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.
Kuo KL; Hung SC; Wei YH; Tarng DC
J Am Soc Nephrol; 2008 Sep; 19(9):1817-26. PubMed ID: 18495964
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients.
Tarng DC; Liu TY; Huang TP
Kidney Int; 2004 Aug; 66(2):820-31. PubMed ID: 15253739
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
6. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
7. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
8. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
9. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
10. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients.
Tarng DC; Huang TP; Wei YH; Liu TY; Chen HW; Wen Chen T; Yang WC
Am J Kidney Dis; 2000 Nov; 36(5):934-44. PubMed ID: 11054349
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
12. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
13. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose.
Guz G; Sahinarslan A; Dhondt AW; Bagdatoglu O; Kavutcu M; Reis KA; Yalçin R; Bali M; Sindel S
Ren Fail; 2004 Nov; 26(6):663-72. PubMed ID: 15600258
[TBL] [Abstract][Full Text] [Related]
14. Effect of vitamin E-bonded membrane on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients.
Tarng DC; Huang TP; Liu TY; Chen HW; Sung YJ; Wei YH
Kidney Int; 2000 Aug; 58(2):790-9. PubMed ID: 10916104
[TBL] [Abstract][Full Text] [Related]
15. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
16. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy.
Lim PS; Wei YH; Yu YL; Kho B
Nephrol Dial Transplant; 1999 Nov; 14(11):2680-7. PubMed ID: 10534512
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
N Engl J Med; 2019 Jan; 380(5):447-458. PubMed ID: 30365356
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Diebold M; Kistler AD
BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
[TBL] [Abstract][Full Text] [Related]
19. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
20. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]